Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach

Ochalek, Jessica; Wang, Haiyin; Gu, Yuanyuan; Lomas, James; Cutler, Henry; Jin, Chunlin

doi:10.1007/s40273-020-00954-y

Record: found
Abstract: not found
Article: not found

Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach

Author(s): Jessica Ochalek , Haiyin Wang , Yuanyuan Gu , James Lomas , Henry Cutler , Chunlin Jin

Publication date (Electronic): August 28 2020

Journal: PharmacoEconomics

Publisher: Springer Science and Business Media LLC

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Health technology assessment has been increasingly used in China, having been legally mandated in 2019, to inform reimbursement decisions and price negotiations between the National Healthcare Security Administration and pharmaceutical companies around the price of new pharmaceuticals. The criteria currently used to judge cost effectiveness and inform pricing negotiations, 3 × GDP per capita, is based on the rule of thumb previously recommended by the World Health Organization rather than an estimate based on an empirical assessment of health opportunity costs.